title: Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders.
abstract: OBJECTIVE
  Some previous studies have reported that ADHD is often comorbid with anxiety disorders. The aim of the present study was to evaluate the effectiveness of reboxetine in treating outpatient children and adolescents with ADHD and comorbid anxiety disorders.
  
  
  METHODS
  In this open-label study, 25 outpatient children and adolescents, aged 6-16 years were selected by convenient sampling and underwent treatment with 4mg reboxetine for four weeks. Data were collected at baseline, two weeks and four weeks after the start of the medication using Conners' Parent Questionnaire, Hamilton's Rating Scale for Anxiety, Clinical Global Assessment Scale, Clinical Global Impression-Severity Scale and Side Effects Form. Data were analyzed using repeated measure, analyses of variance (ANOVA), Tukey post hoc test and paired t-test.
  
  
  RESULTS
  There were significant reduction in the total score of ADHD (F = 31.441; P <0.001) at the end of the treatment compared to baseline (Table 1). The differences between T0 and T2 in the subscales of attention deficit, hyperactivity and confrontation (F = 20.691; P <0.001, F = 28.810; P < 0.001, and F = 17.463; P <0.001, respectively) were also significant. Findings also indicated significant differences between T0 and T1 (P<0.01) and T1 and T2 (P<0.01) in all of the subscales except for confrontation. A significant improvement was observed in the severity of ADHD and anxiety disorders during different courses of the treatment (p<0.001). No significant changes were observed in systolic and diastolic blood pressure and pulse and weight of the patients during the study. The most common complications were headache and anorexia.
  
  
  CONCLUSIONS
  The short-term treatment with reboxetine was effective in improving ADHD with comorbid anxiety disorders. Therefore, reboxetine could be used as a treatment option for ADHD in those children who experience comorbid anxiety disorders or in those who are non-responsive or intolerant to methylphenidate.
authors: Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors: Forough
authors: F
authors: Riahi
authors: Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
authors: Ashraf
authors: A
authors: Tashakori
authors: Ahvaz Shahid Chamran University, Ahvaz, Iran.
authors: Sakineh
authors: S
authors: Izadi-Mazidi
authors: Behbahan Industrial University, Behbahan, Iran.
authors: Mohammad
authors: M
authors: Salehi-Veysi
keywords: Attention deficit-hyperactivity disorder (ADHD); Conners’ Parent questionnaire; Hamilton’s Anxiety Rating Scale; Reboxetine
references: Acta Paediatr. 2011 Mar;100(3):402-6
references: 21054512
references: J Child Adolesc Psychopharmacol. 2005 Apr;15(2):259-69
references: 15910210
references: J Child Adolesc Psychopharmacol. 2001 Summer;11(2):203-4
references: 11436962
references: Eur Child Adolesc Psychiatry. 2000 Sep;9(3):195-201
references: 11095042
references: Int J Neuropsychopharmacol. 2004 Mar;7(1):77-97
references: 14733627
references: J Child Adolesc Psychopharmacol. 2006 Dec;16(6):803-4
references: 17201625
references: Child Adolesc Psychiatry Ment Health. 2007 Sep 28;1(1):11
references: 17903242
references: J Neurochem. 2004 Feb;88(4):917-27
references: 14756813
references: BMC Psychiatry. 2009 Apr 14;9:15
references: 19366449
references: Am J Psychiatry. 1993 Dec;150(12):1792-8
references: 8238632
references: Hum Psychopharmacol. 2010 Nov;25(7-8):570-6
references: 21312292
references: Br J Med Psychol. 1959;32(1):50-5
references: 13638508
references: Nervenarzt. 2002 Feb;73(2):149-54
references: 11975091
references: J Child Adolesc Psychopharmacol. 2007 Dec;17(6):803-12
references: 18315452
references: Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I102-16
references: 15322961
references: Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
references: 6639293
references: J Am Acad Child Adolesc Psychiatry. 1996 Apr;35(4):409-32
references: 8919704
references: Postgrad Med. 2010 Sep;122(5):97-109
references: 20861593
references: Expert Opin Pharmacother. 2000 May;1(4):771-82
references: 11249515
references: Paediatr Drugs. 2009;11(3):203-26
references: 19445548
references: CNS Spectr. 2003 Apr;8(4):253-8
references: 12679740
references: Eur Child Adolesc Psychiatry. 2009 Jan;18(1):53-9
references: 18563471
references: Adv Ther. 2006 Nov-Dec;23(6):974-87
references: 17276965
references: J Clin Psychiatry. 2002 Jan;63(1):31-7
references: 11838623
references: J Child Adolesc Psychopharmacol. 2008 Apr;18(2):179-84
references: 18439114
references: Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30
references: 15322953
references: J Am Acad Child Adolesc Psychiatry. 2005 May;44(5):428-33
references: 15843764
references: Am J Geriatr Psychiatry. 2008 Oct;16(10):813-8
references: 18827227
references: Clin Neuropharmacol. 2009 Jul-Aug;32(4):179-82
references: 19644227
references: J Am Acad Child Adolesc Psychiatry. 2003 Jun;42(6):642-50
references: 12921471
references: Arch Gen Psychiatry. 1996 May;53(5):437-46
references: 8624187